What does this research mean for the field?

LCZ696 is superior to enalapril in reducing the risks of death and hospitalization for heart failure in patients with heart failure. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

August 30, 2014Open Access

Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

Resultado clave

LCZ696 was superior to enalapril in reducing the risks of death and hospitalization for heart failure in patients with heart failure.

PICO estructurado

Does LCZ696 reduce the risks of death and hospitalization for heart failure compared to enalapril in patients with heart failure?

Población

Patients with heart failure

Intervención

LCZ696 (Angiotensin-Neprilysin Inhibition)

Comparador

Enalapril

Resultado

Death and hospitalization for heart failurehard clinical

LCZ696 (angiotensin-neprilysin inhibition) is superior to enalapril in reducing death and heart failure hospitalization in patients with heart failure.

Resultado numérico

Tasa de eventos absoluta: 0% vs 0%

Resumen

LCZ696 was superior to enalapril in reducing the risks of death and of hospitalization for heart failure. (Funded by Novartis; PARADIGM-HF ClinicalTrials.gov number, NCT01035255.).

Leer artículo completoexternamente

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

McMurray et al. (Sat,) reported a other. LCZ696 was superior to enalapril in reducing the risks of death and hospitalization for heart failure in patients with heart failure.

synapsesocial.com/papers/697a3929e3885199a727c623 https://doi.org/https://doi.org/10.1056/nejmoa1409077

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo